{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:37:41Z","timestamp":1770719861692,"version":"3.49.0"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,10,14]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Cancer is the second leading cause of mortality worldwide. Despite several advances\nmade in the treatment strategies, the cure for cancer remains still a challenge. Currently used treatment modalities\npose several side effects and remain ineffective in the later stages. Thiazolidinediones (TZDs) have been\nshown to possess anti-cancer activity in several in vitro models.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The objective of this study was to assess the effect of novel synthesized thiazolidinedione derivatives\non three selected cancer cell lines viz., human breast adenocarcinoma cell line (MCF-7), lung adenocarcinoma\n(A549) and colorectal carcinoma (HT29). This study also aimed to evaluate the anti-inflammatory and\nDNA binding activity of the synthesized derivatives.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The synthesized thiazolidinedione derivatives were screened for their in vitro anti-cancer activity on\nthe human breast adenocarcinoma cell line (MCF-7), lung adenocarcinoma (A549) and colorectal carcinoma\n(HT29) using the Methyl Thaizolyl Tetrazolium (MTT) Assay. They were also evaluated for in vitro antiinflammatory\nactivity using albumin denaturation method, DNA binding activity and hemocompatibility.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Compounds 5a, 5b, 5d, 6c and 6d showed IC50 of 30.19, 41.56, 65.97, 60.16 and 50.41\u03bcM respectively\non breast adenocarcinoma (MCF-7), IC50 of 49.75, 51.42, 65.43, 61.94 and 56.80\u03bcM on lung adenocarcinoma\n(A549) and 38.11, 45.58, 71.24, 53.15 and 51.25\u03bcM on colorectal carcinoma (HT29). In the hemolysis assay,\ncompounds 5a and 5b were found to be nontoxic and nonhemolytic to human erythrocytes. Five compounds\npossessed significant anticancer and anti-inflammatory activity. Three of them are Mannich bases, whereas the\nremaining two are aryl acyl derivatives.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The in vitro results (anticancer and anti-inflammatory) showed that the 4-chloro anilinomethyl\nsubstitution at third position and thiophenoethenyl at the fifth position of thiozolidinedione (5a) emerged as the\nmost effective derivative on all the tested cancer cell lines. A higher DNA binding affinity of the test compounds\nwas also found.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200424102615","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T15:26:56Z","timestamp":1587742016000},"page":"1704-1713","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives"],"prefix":"10.2174","volume":"20","author":[{"given":"Nadine","family":"Uwabagira","sequence":"first","affiliation":[{"name":"Division of Biochemistry, Department of Studies in Chemistry, Mangalore University, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balladka K.","family":"Sarojini","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Studies in Chemistry, Mangalore University, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwini","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.semcancer.2015.09.007","volume":"35","author":"Block K.I.","year":"2015","unstructured":"Block K.I.; Gyllenhaal C.; Lowe L.; Amedei A.; Amin A.R.M.; Amin A.; Aquilano K.; Arbiser J.; Arreola A.; Arzumanyan A.; Ashraf S.S.; Azmi A.S.; Benencia F.; Bhakta D.; Bilsland A.; Bishayee A.; Blain S.W.; Block P.B.; Boosani C.S.; Carey T.E.; Carnero A.; Carotenuto M.; Casey S.C.; Chakrabarti M.; Chaturvedi R.; Chen G.Z.; Chen H.; Chen H.; Chen S.; Chen Y.C.; Choi B.K.; Ciriolo M.R.; Coley H.M.; Collins A.R.; Connell M.; Crawford S.; Curran C.S.; Dabrosin C.; Damia G.; Dasgupta S.; DeBerardinis R.J.; Decker W.K.; Dhawan P.; Diehl A.M.; Dong J.T.; Dou Q.P.; Drew J.E.; Elkord E.; El-Rayes B.; Feitelson M.A.; Felsher D.W.; Ferguson L.R.; Fimognari C.; Firestone G.L.; Frezza C.; Fujii H.; Fuster M.M.; Generali D.; Georgakilas A.G.; Gieseler F.; Gilbertson M.; Green M.F.; Grue B.; Guha G.; Halicka D.; Helferich W.G.; Heneberg P.; Hentosh P.; Hirschey M.D.; Hofseth L.J.; Holcombe R.F.; Honoki K.; Hsu H.; Huang G.S.; Jensen L.D.; Jiang W.G.; Jones L.W.; Karpowicz P.A.; Keith W.N.; Kerkar S.P.; Khan G.N.; Khatami M.; Ko Y.H.; Kucuk O.; Kulathinal R.J.; Kumar N.B.; Kumar H.M.C.; Kwon B.S.; Le A.; Lea M.A.; Lee H.Y.; Lichtor T.; Lin L.T.; Locasale J.W.; Lokeshwar B.L.; Longo V.D.; Lyssiotis C.A.; MacKenzie K.L.; Malhotra M.; Marino M.; Martinez-Chantar M.L.; Matheu A.; Maxwell C.; McDonnell E.; Meeker A.K.; Mehrmohamadi M.; Mehta K.; Michelotti G.A.; Mohammad R.M.; Mohammed S.I.; Morre D.J.; Muqbil I.; Muralidhar V.; Murphy M.P.; Nagaraju G.P.; Nahta R.; Niccolai E.; Nowsheen S.; Panis C.; Pantano F.; Parslow V.R.; Pawelec G.; Pedersen P.L.; Poore B.; Poudyal D.; Prakash S.; Prince M.; Raffaghello L.; Rathmell J.C.; Rathmell W.K.; Ray S.K.; Reichrath J.; Rezazadeh S.; Ribatti D.; Ricciardiello L.; Robey R.B.; Rodier F.; Rpasinghe V.H.P.; Russo G.L.; Ryan E.P.; Samadi A.K.; Sanchez-Garcia I.; Sanders A.J.; Santini D.; Sarkar M.; Sasada T.; Saxena N.K.; Shackelford R.E.; Sharma D.; Shin D.M.; Sidransky D.; Siegelin M.D.; Signori E.; Singh N.; Sivanand S.; Sliva D.; Smythe C.; Spagnuolo C.; Stafforini D.M.; Stagg J.; Subbarayan P.R.; Sundin T.; Talib W.H.; Thompson S.K.; Tran P.T.; Ungefroren H.; Vander M.G.; Venkateswaran V.; Dass S.; A broad-spectrum integrative design for cancer prevention and therapy. Semin Cancer Biol 2015,35,276-304","journal-title":"Semin Cancer Biol"},{"key":"ref=2","author":"Block Keith I.","year":"2009","unstructured":"Block Keith I.;  Life over cancer: The Block Cancer Program for Integrative Cancer Treatment 2009","journal-title":"Life over cancer: The Block Cancer Program for Integrative Cancer Treatment"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1038\/srep05360","volume":"4","author":"Wei J.Y.","year":"2014","unstructured":"Wei J.Y.; Huang W.H.; Du C.W.; Qui S.Q.; Wei X.L.; Liu J.; Zhang G.J.; Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China. Sci Rep 2014,4,5360","journal-title":"Sci Rep"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15537\/smj.2016.1.13016","volume":"37","author":"AlZaman A.S.","year":"2016","unstructured":"AlZaman A.S.; Mughal S.A.; AlZaman Y.S.; AlZaman E.S.; Correlation between hormone receptor status and age and its prognostic implications in breast cancer patients in Bahrain. Saudi Med J 2016,37(1),37-42","journal-title":"Saudi Med J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1097\/MD.0000000000002989","volume":"95","author":"Shen C.C.","year":"2016","unstructured":"Shen C.C.; Hu M.D.L.; Hu W.Y.; Chang W.H.; Tang P.; Chen P.L.; Chen P.M.; Chen M.T.; Su T.P.; The risk of cancer patients with obsessive compulsive disorder. Medicine 2016,95(9),2989","journal-title":"Medicine"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/oemed-2016-103951.358","volume":"114","author":"Heikkila K.","year":"2016","unstructured":"Heikkila K.; Nyberg S.T.; Madsen I.E.; DeVroom E.; Alfredssons L.; Bjorner J.J.; Borritz M.; Burr H.; Erbel R.; Ferrie J.E.; Fransson E.I.; Geuskens G.A.; Hooftman W.E.; Houtman I.L.; Ckel K.J.; Knutsson A.; Koskenvuo M.; Lunau T.; Nielsen M.L.; Nordin M.; Oksanen T.; Pejtersen J.H.; Pentti J.; Shipley M.J.; Steptoe A.; Suominen M.; Oksanen T.; Pejtersen J.H.; Pentti J.; Shipley M.J.; Steptoe A.; Suominen S.B.; Theorell T.; Vahtera J.; Westerholm P.J.M.; Westerlund H.; Dragano N.; Rugulies R.; Kawachi I.; Batty G.D.; Manoux A.S.; Virtanen M.; Kivima M.; Long working hours and cancer risk: A multi-cohort study. Br J Cancer 2016,114,813-818","journal-title":"Br J Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"Herbst R.S.","year":"2018","unstructured":"Herbst R.S.; Morrgensztern D.; Boshoff C.; The biology and management of non-small cell lung cancer. Nature 2018,553,446-454","journal-title":"Nature"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctrv.2016.01.003","volume":"44","author":"Fennell D.A.","year":"2016","unstructured":"Fennell D.A.; Summers Y.; Cadranel J.; Benepal T.; Christoph D.C.; Lal R.; Das M.; Maxwell F.; Visseren-Grul C.; Ferry D.; Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 2016,44,42-50","journal-title":"Cancer Treat Rev"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1053\/jhep.2001.24024","volume":"33","author":"Koga H.","year":"2001","unstructured":"Koga H.; Sakisaka S.; Harada M.; Takagi T.; Hanada S.; Taniguchi E.; Kawaguchi T.; Sasatomi K.; Kimura R.; Hashimoto O.; Uena T.; Yano H.; Kojiro M.; Sata M.; Involvement of p21WAF1\/Cip1, p27Kip1and p18INK4c in troglitazone-induced cell cycle arrest in human hepatoma cell lines. Hepatology 2001,33(5),1087-1097","journal-title":"Hepatology"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.bmcl.2004.02.087","volume":"14","author":"Fan Y.H.","year":"2004","unstructured":"Fan Y.H.; Chen A.; Natarajan Y.; Guo F.; Harbinski J.; Iyasere W.; Christ H.; Aktas J.A.; Structure activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg Chem Med Lett 2004,14,2547-2550","journal-title":"Bioorg Chem Med Lett"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-84138-5_11","author":"Aapro M.S.","year":"1991","unstructured":"Aapro M.S.;  In: Supportive Care in Cancer Patients II. Recent Results in Cancer Research, Senn, H.J.; Glaus, A. (Eds). Springer: Berlin, Heidelberg;\n121 1991"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199809059229","volume":"31","author":"Reiser M.","year":"1998","unstructured":"Reiser M.; Schnell R.; Straub G.; Borchmann P.; Wilhelm M.; \u00dcbelacker R.; W\u00f6rmann B.; M\u00fcnch R.; Diehl V.; Engert A.; Dize (Dexamethasone, idarubicin and contious infusion of ifosfamide and etoposide): An effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998,31,359-366","journal-title":"Leuk Lymphoma"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","volume":"342","year":"2000","unstructured":"Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med The Italian Group for Antiemetic Research2000,342(21),1554-1559","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"Rayburn E.R.","year":"2009","unstructured":"Rayburn E.R.; Ezell S.; Zhang R.; Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009,1(1),29-43","journal-title":"Mol Cell Pharmacol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","volume":"110","author":"Panigrahy D.","year":"2002","unstructured":"Panigrahy D.; Singer S.; Shen Q.L.; Butterfield C.E.; Freedman D.A.; Chen E.J.; Moses M.A.; Kilroy S.; Duensing S.; Fletcher C.; Fletcher J.A.; Hlatky L.; Hahnfeldt P.; Folkman J.; Kaipainen A.; PPAR\u1d67 ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002,110(7),923-932","journal-title":"J Clin Invest"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bioorg.2014.05.006","volume":"56","author":"Kar K.","year":"2014","unstructured":"Kar K.; Krithika U.; Basu P.; Kumar S.S.; Reji A.; Kumar B.P.; Design, synthesis and glucose uptake of some novel glitazones. Bioorg Chem 2014,56,27-33","journal-title":"Bioorg Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1016\/j.ejmech.2010.07.014","volume":"45","author":"Patil V.","year":"2010","unstructured":"Patil V.; Tilekar K.; Mehendale M.S.; Mohan R.; Ramaa C.S.; Synthesis and primary cytotoxicity of new 5- benzylidene-2, 4-thiazolidinedione derivatives. Eur J Med Chem 2010,45,4539-4544","journal-title":"Eur J Med Chem"},{"key":"ref=18","first-page":"6213","volume":"61","author":"Palakurthi S.S.","year":"2001","unstructured":"Palakurthi S.S.; Aktas H.; Grubissich L.M.; Mortensen R.M.; Halperin J.A.; Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001,61(16),6213-6218","journal-title":"Cancer Res"},{"key":"ref=19","first-page":"975","volume":"95","author":"Madhuri M.","year":"2014","unstructured":"Madhuri M.; Prasad C.; Avupati V.R.; In silico protein-ligand docking studies on thiazolidinediones as potential anticancer agents. Int J Comput Appl 2014,95,975-8887","journal-title":"Int J Comput Appl"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mc.20593","volume":"49","author":"Yan K.","year":"2010","unstructured":"Yan K.; Yao C.; Chang H.; Lai G.; Cheng A.; Chuang S.; The synergistic anticancer effect of troglitazone combined with asprin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog 2010,49,235-246","journal-title":"Mol Carcinog"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejmech.2013.10.005","volume":"70","author":"Chinthala Y.","year":"2013","unstructured":"Chinthala Y.; Domatti A.K.; Sarfaraz A.; Singh S.P.; Arigari N.K.; Gupta N.; Satya K.V.N.; Kumar J.K.; Khan F.; Tiwari A.K.; Paramjit G.; Synthesis, biological evaluation and molecular docking studies of some novel thiazolidinediones with triazole ring. Eur J Med Chem 2013,70,308-314","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejmech.2014.10.025","volume":"87","author":"Asati V.","year":"2014","unstructured":"Asati V.; Mahapatra D.K.; Bharti S.K.; Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. Eur J Med Chem 2014,87,814-833","journal-title":"Eur J Med Chem"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejmech.2016.08.029","volume":"124","author":"Sharma P.","year":"2016","unstructured":"Sharma P.; Reddy T.S.; Thummuri D.; Senwar K.R.; Kumar N.P.; Naidu V.G.M.; Bhargava S.K.; Shankaraiah N.; Synthesis and biological evaluation of new benzimidazole-thiazoldinedione hybrids as potential cytotoxic and apoptosis inducing agents. Eur J Med Chem 2016,124,608-621","journal-title":"Eur J Med Chem"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1007\/s00044-013-0902-z","volume":"23","author":"Barreto M.J.","year":"2014","unstructured":"Barreto M.J.; Galdino M.L.; Pereira D.T.M.; Cruz J.; Rabello M.M.; Alves M.C.; Hernandes M.Z.; Pitta I.R.; Galdino S.L.; Galdino M.; Synthesis, in vitro anticancer activity and in silico study of new disubstituted thiazolidinedione derivatives. Med Chem Res 2014,23,3220-3226","journal-title":"Med Chem Res"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40199-014-0086-1","volume":"23","author":"Bahare R.S.","year":"2015","unstructured":"Bahare R.S.; Ganguly S.; Choowongkomon K.; Seetaha S.; Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted \u2013benzylidine-2,4-thiazolidinediones. DARU J Pharm Sci 2015,23(6),1-15","journal-title":"DARU J Pharm Sci"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.bmc.2010.01.021","volume":"18","author":"Youssef A.M.","year":"2010","unstructured":"Youssef A.M.; White M.S.; Villanueva E.B.; El-Ashmawy I.M.; Klegeris A.; Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. Bioorg Med Chem 2010,18,2019-2028","journal-title":"Bioorg Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0960-894X(01)00063-4","volume":"11","author":"Hu B.","year":"2001","unstructured":"Hu B.; Ellingboe J.; Gunawan I.; Han S.; Largis E.; Li Z.; Malamas M.; Mulvey R.; Oliphant A.; Sum F.W.; Tillett J.; Wong V.; 2,4-Thiazolidinediones as potent and selective human \u03b23 agonists. Bioorg Med Chem Lett 2001,11(6),757-760","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2015.12.049","volume":"109","author":"Darwish K.M.","year":"2016","unstructured":"Darwish K.M.; Salama I.; Mostafa S.M.; Gomaa M.S.; Helal M.A.; Design, synthsis and biological evaluation of novel thiazolidinediones as PPAR\u1d67-FFAR1 dual agonists. Eur J Med Chem 2016,109,157-172","journal-title":"Eur J Med Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1677\/ERC-07-0226","volume":"15","author":"Costa V.","year":"2008","unstructured":"Costa V.; Paonessa F.; Chiefari E.; Palaia L.; Brunetti G.; Gulletta E.; Fusco A.; Brunetti A.; The insulin receptor: A new anticancer target for peroxisome proliferator-activated receptor-\u1d67 (PPAR\u1d67) and thiazolidinedione- PPAR\u1d67 agonists. Endocr Relat Cancer 2008,15,325-335","journal-title":"Endocr Relat Cancer"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.bmc.2013.01.029","volume":"21","author":"Jain V.S.","year":"2013","unstructured":"Jain V.S.; Vora D.K.; Ramaa C.S.; Thiazolidine-2,4-diones: Progress towards multifarious applications. Bioorg Med Chem 2013,21,1599-1620","journal-title":"Bioorg Med Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMp1309610","volume":"369","author":"Hiatt W.R.","year":"2013","unstructured":"Hiatt W.R.; Kaul S.; Smith R.J.; The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med 2013,369,1285-1287","journal-title":"N Engl J Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.lfs.2018.04.057","volume":"203","author":"Zong J.","year":"2018","unstructured":"Zong J.; Liao X.; Ren B.; Wang D.; The antidepressant effects of rosiglitazone on rats with depression induced by neuropathic pain. Life Sci 2018,203,315-322","journal-title":"Life Sci"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.bmcl.2006.12.040","volume":"17","author":"Hossain S.U.","year":"2007","unstructured":"Hossain S.U.; Bhattacharya S.; Synthesis of O-plenylated derivatives of 5-benzylidene-2,4-thiazolidinediones and evaluation of their free radical scavenging activity as well as effect on some phase II antioxidant\/detoxifying enzymes. Bioorg Med Chem 2007,17,1149-1154","journal-title":"Bioorg Med Chem"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1016\/j.bmcl.2013.04.092","volume":"23","author":"Min G.","year":"2013","unstructured":"Min G.; Lee S.; Kim H.; Han Y.; Lee R.; Jeong D.G.; Han D.C.; Kwon B.; Rhodamine-based PL3-inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg Med Chem Lett 2013,23,3769-3774","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1016\/j.bmcl.2004.08.017","volume":"14","author":"Chen H.","year":"2004","unstructured":"Chen H.; Fan Y.; Natarajan A.; Guo Y.; Iyasere J.; Harbinski F.; Luus L.; Christ W.; Aktas H.; Halperin J.A.; Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg Med Chem Lett 2004,14,5401-5405","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.26452\/ijrps.v10i2.379","volume":"10","author":"Geetha B.","year":"2019","unstructured":"Geetha B.; Swarnalatha G.; Subba R.G.; Biological evaluation of synthesized thiazolidinedione derivatives for antidiabetic activity on STZ caused diabetes in rat. Int J Res Sci 2019,10,1042-1048","journal-title":"Int J Res Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.2174\/1389557519666190513093618","volume":"19","author":"Kumar H.","year":"2019","unstructured":"Kumar H.; Deep A.; Marwaha R.K.; Chemical synthesis, mechanism of action and anticancer potential of medicinally important thiazolidin-2,4-dione derivatives: A review. Mini Rev Med Chem 2019,19(18),1474-1516","journal-title":"Mini Rev Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13065-017-0357-2","volume":"11","author":"Sucheta S.T.","year":"2017","unstructured":"Sucheta S.T.; Verma P.K.; Biological potential of thiazolidinedione derivatives of synthetic origin. Chem Cent J 2017,11,130","journal-title":"Chem Cent J"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/carcin\/bgp260","volume":"30","author":"Christopher M.L.","year":"2009","unstructured":"Christopher M.L.; Donna M.K.; Kieu C.D.; Marcie J.G.; Cindy L.T.; Leah A.D.; Thomas H.M.; Christine A.S.; Steven A.B.; Rotiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 2009,30,2095-2099","journal-title":"Carcinogenesis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/1471-2407-12-410","volume":"12","author":"Mazzone P.J.","year":"2012","unstructured":"Mazzone P.J.; Rai H.; Beukemann M.; Xu M.; Jain A.; Sasidhar M.; The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012,12,410","journal-title":"BMC Cancer"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2006.07.2777","volume":"25","author":"Govindarajan R.","year":"2007","unstructured":"Govindarajan R.; Ratnasinghe L.; Simmons D.L.; Siegel E.R.; Midathada M.V.; Kim L.; Kim P.J.; Owens R.J.; Lang N.P.; Thiazolidinediones and the risk of lung, prostate and colon cancer in patients with diabetes. J Clin Oncol 2007,25,1476-1481","journal-title":"J Clin Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1158\/1078-0432.CCR-08-1128","volume":"14","author":"Girnun G.D.","year":"2008","unstructured":"Girnun G.D.; Chen L.; Silvaggi J.; Drapkin R.; Chirieac L.R.; Padera R.F.; Upadhyay R.; Vafai S.B.; Weissleder R.; Mahmood U.; Naseri E.; Buckley S.; Li D.; Force J.; McNamara K.; Demetri G.; Spiegelman B.M.; Wong K.K.; Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 2008,14(20),6478-6486","journal-title":"Clin Cancer Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","volume":"15","author":"Benson A.B.","year":"2017","unstructured":"Benson A.B.; Venool A.P.; Cederquist L.; Chan E.; Chen Y.; Cooper H.S.; Deming D.; Engstrom P.F.; Enziger P.C.; Fichera A.; Grem J.L.; Grothey A.; Hochster H.S.; Hoffe S.; Hunt S.; Kamel A.; Kirilcuk N.; Krishnamurthi S.; Messersmith W.A.; Mulcahy M.F.; Murphy J.D.; Nurkin S.; Saltz L.; Sharma S.; Shibata D.; Skibber J.M.; Colon cancer 1, 2017. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017,15(3),370-398","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.21577\/0103-5053.20180167","volume":"30","author":"Raissa K.C.","year":"2019","unstructured":"Raissa K.C.; Jamerson F.; Moreira H.A.; Pinto O.G.; Camargo L.T.; Naves P.L.; Camargo A.J.; Ribeiro L.; Ramos L.M.; Synthesis, antimicrobial activity and structure-activity relationship of some5-arylidene-thiazolidine-2,4-dione derivatives. J Braz Chem Soc 2019,30(1),164-172","journal-title":"J Braz Chem Soc"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1016\/j.bmc.2007.06.049","volume":"15","author":"Bozda\u011f-D\u00fcndar O.","year":"2007","unstructured":"Bozda\u011f-D\u00fcndar O.; Ozgen O.; Mente\u015fe A.; Altanlar N.; Atli O.; Kendi E.; Ertan R.; Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4-dione derivatives. Bioorg Med Chem 2007,15(18),6012-6017","journal-title":"Bioorg Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"Mosmann T.","year":"1983","unstructured":"Mosmann T.; Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983,65(1-2),55-63","journal-title":"J Immunol Methods"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1021\/acsmedchemlett.5b0016","volume":"6","author":"Sashidhara K.V.","year":"2015","unstructured":"Sashidhara K.V.; Rao K.B.; Kushwaha P.; Modukuri R.K.; Singh P.; Soni I.; Shukla P.K.; Chopra S.; Pasupuleti M.; Novel chalcone-thiazole-hybrids as potent inhibitors of drug resistance Staphylococcus aureus. ACS Med Chem Lett 2015,6(7),809-813","journal-title":"ACS Med Chem Lett"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.2042-7158.1968.tb09718.x","volume":"20","author":"Mizushima Y.","year":"1968","unstructured":"Mizushima Y.; Kobayashi M.; Interaction of anti-inflammatory drugs with serum proteins, especially with some biologically active proteins. J Pharm Pharmacol 1968,20(3),169-173","journal-title":"J Pharm Pharmacol"},{"key":"ref=49","first-page":"221","volume":"3","author":"Sakat S.","year":"2009","unstructured":"Sakat S.; Preeti T.; Juvekar A.; In vitro anti-inflammatory activity of aqueous and methanol extracts of Erythrina indica Lam leave. Pharmacologyonline 2009,3,221-229","journal-title":"Pharmacologyonline"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1021\/bi00292a024","volume":"22","author":"Pasternack R.F.","year":"1983","unstructured":"Pasternack R.F.; Gibbs E.J.; Villafranca J.J.; Interactions of porphyrins with nucleic acids. Biochemistry 1983,22(23),5409-5417","journal-title":"Biochemistry"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1021\/ja00319a043","volume":"106","author":"Barton J.","year":"1984","unstructured":"Barton J.; Danishefisky A.; Goldberg J.; Thris (phenanthroline) ruthenium (II): Streoselectivity in binding to DNA. J Am Chem Soc 1984,106,2172-2176","journal-title":"J Am Chem Soc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.saa.2010.12.056","volume":"78","author":"Raman N.","year":"2011","unstructured":"Raman N.; Sobba S.; Thamaraichelvan A.; A novel bioactive derived Schiff base and its transition metal complexes as selective DNA binding agents. Spectrochim Acta  Part A 2011,78,888-898","journal-title":"Spectrochim Acta  Part A"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1021\/bi00394a013","volume":"26","author":"Wolfe A.","year":"1987","unstructured":"Wolfe A.; Shimer G.; Meehan T.; Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA. Biochemistry 1987,26,6392-6396","journal-title":"Biochemistry"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/bio.3227","volume":"32","author":"Hassan M.F.","year":"2017","unstructured":"Hassan M.F.; Rauf A.; Synthesis and the study on the binding of the thiazol-2(3H) ylidine derivative with human serum albumin using spectroscopic and molecular docking methods. Luminescence 2017,32,602-612","journal-title":"Luminescence"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181287\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/181287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T20:15:15Z","timestamp":1614456915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181287\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":54,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,10,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200424102615","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}